Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter
Crossing the Blood-Brain Barrier with AAVs: What’s After SMA?
The 2009 discovery that the AAV9 serotype can deliver genes across the blood-brain barrier (BBB) spurred the rapid development of a recently FDA-approved gene therapy for spinal muscular atrophy (SMA). The suc...